Compare Globus Medical Inc. Class A Common Stock (GMED) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Plby Group Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Plby Group Inc trades at $0.97 (market cap $118.61M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 86.4× Plby Group Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Plby Group Inc for 24 Days on average.
| GMED | PLBY | |
|---|---|---|
Market Cap | $10.25B | $118.61M |
Volume | 1,059,528 | 1,149,362 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $2.71 |
52-Week Low | $58.33 | $0.98 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $9.76B | $264.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PLBY Group trades at $1.02, up 2.7% today, amid a bearish technical outlook with mixed fundamentals. The company shows improving financial trends with revenue stabilizing around $120M and narrowing losses, but remains unprofitable with negative shareholder equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
While analyst consensus is strongly bullish (75% buy ratings), significant risks persist including high debt levels, negative equity, and inconsistent earnings performance. The stock's valuation appears stretched with a P/E of 51, requiring sustained operational improvement to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
